HISTIOCITOSIS MALIGNA. APORTACION DE UN CASO TRATADO CON PROMACE-CYTABOM MAS G-CSF

Background: Malignant histiocytosis is a disease of the mononuclear hematopoietic system with an upper mean survival of 6 months. Cytotoxic treatment may improve this disease. Clinical Observation: The case of a patient diagnosed with malignant histiocytosis who was treated with the cytotoxic polychemotherapy PROMACE-CYTABOM plus G-CSF schedule is presented. Complete response was determined after 3 cycles with the same being consolidated with three further cycles. The patient currently remains in complete remission after 2 years of follow up. The data supporting the administration of this treatment in the literature is reviewed. Conclusion: Chemotherapy with PROMACE-CYTABOM is an effective treatment in malignant histiocytosis.